

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*

**WEGO 威高**

**山東威高集團醫用高分子製品股份有限公司**  
**Shandong Weigao Group Medical Polymer Company Limited** \*

*(a joint stock limited company incorporated in the People's Republic of China with limited liability)*

**(Stock Code: 1066)**

**PROFIT WARNING**  
**AND**  
**CHANGE OF CHIEF FINANCIAL OFFICER**

This announcement is made by the Company pursuant to Rule 13.09(2) of the Listing Rules and the Inside Information Provisions under Part XIVA of the SFO.

The Board wishes to inform the Shareholders and potential investors that taking into account the financial impact resulted from the disposal of the equity interests in Biosensors International Group, Ltd., which as stated in the Company's announcement dated 21 November 2013 is expected to result in a loss in total comprehensive income in the amount of approximately RMB449 million, the Group expects to record a significant decrease in consolidated profit attributable to owners of the Company for the year ended 31 December 2013 as compared with the consolidated profit attributable to owners of the Company recorded for the year ended 31 December 2012.

This profit warning announcement is only based on the preliminary review by the Company's management of the Group's management accounts which have not been reviewed by the independent auditor or the audit committee of the Company.

Details of the Group's performance will be disclosed in the final results announcement of the Group for its financial year ended 31 December 2013 before the end of March 2014.

\* For identification purpose only

**Shareholders and potential investors are advised to exercise caution when dealing in the shares of the Company.**

The Board also announces that Mr. Ju Hongfeng has resigned as the chief financial officer of the Company and Mr. Jason Cui Jin has been appointed as the chief financial officer of the Company with effect from 28 January 2014.

## **PROFIT WARNING**

This announcement is made by Shandong Weigao Group Medical Polymer Company Limited (the “**Company**”, and together with its subsidiaries, the “**Group**”) pursuant to Rule 13.09(2) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”) and the Inside Information Provisions under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong) (the “**SFO**”).

Based on a preliminary review by the Company’s management of the management accounts of the Group, the board of the Company (the “**Board**”) wishes to inform holders of shares of the Company (the “**Shareholders**”) and potential investors that taking into account the financial impact resulted from the disposal of the equity interests in Biosensors International Group, Ltd., which as stated in the Company’s announcement dated 21 November 2013 is expected to result in a loss in total comprehensive income in the amount of approximately RMB449 million, the Group expects to record a significant decrease in consolidated profit attributable to owners of the Company for the year ended 31 December 2013 as compared with the consolidated profit attributable to owners of the Company recorded for the year ended 31 December 2012.

This profit warning announcement is only based on the preliminary review by the Company’s management of the Group’s management accounts which have not been reviewed by the independent auditor or the audit committee of the Company.

The Company is in the process of finalizing the annual results of the Group for the financial year ended 31 December 2013. Details of the Group’s performance will be disclosed in the final results announcement of the Group for its financial year ended 31 December 2013 before the end of March 2014.

**Shareholders of the Company and potential investors are advised to exercise caution when dealing in the shares in the Company.**

## **RESIGNATION OF CHIEF FINANCIAL OFFICER**

The Board announces that Mr. Ju Hongfeng (“Mr. Ju”) has resigned as the chief financial officer of the Company with effect from 28 January 2014 and has been appointed as a vice president in supply chain management. As the Group continues to grow and expand, supply chain management is a core competence that will have to be enhanced. Mr. Ju has been with the Group since 2002. With his strong experience in finance and accounting, his knowledge and relationship built over the year both within and outside the Group, he is well suited to take up new role with the responsibility to strengthen the Group’s supply chain management. Mr. Ju’s new role will encompass planning and management of all activities involved in sourcing, procurement and logistics management of the supply chain.

Mr. Ju has confirmed that he has no disagreement with the Board, and there is no matter in respect of his resignation that needs to be brought to the attention of the Shareholders of the Company.

The Company expresses its sincere gratitude to Mr. Ju for his valuable contributions as chief financial officer to the Company during his term of office and a warm welcome on his new role.

## **APPOINTMENT OF CHIEF FINANCIAL OFFICER**

The Board has appointed Mr. Cui Jin, Jason (“Mr. Cui”) as the chief financial officer of the Company with effect from 28 January 2014.

Mr. Cui, aged 42, has over 15 years working experience in accounting, costing, budgeting, treasury management, financial planning and analysis. Mr. Cui joined Weigao Holding Company Limited, the holding company of the Group, in August 2011 as the chief financial controller. Mr. Cui worked for Bard Medical Device Beijing Limited initially as finance manager between November 2006 to March 2008 and was its finance director between April 2008 to July 2011. Mr. Cui worked for Velux China Limited as the finance manager (August 2004 to October 2006), Kerr-Mcgee China Petroleum Limited as budget coordinator and project cost controller (September 2002 to July 2004), Xian Janssen Pharmaceutical Company Limited as finance manager (September 2000 to September 2002) and Deloitte Touche Tohmatsu as senior auditor (September 1998 to August 2000).

Mr. Cui graduated from Peking University with a bachelor degree in finance and obtained a master degree major in enterprise management and accounting from Peking University.

The Board takes this opportunity to extend a warm welcome to Mr. Cui to his appointment.

By order of the Board  
**Shandong Weigao Group Medical Polymer Company Limited**  
**Chen Xue Li**  
*Chairman*

Weihai, Shandong, the PRC  
28 January 2014

*As at the date of this announcement, the Board comprises:*

Mr. Zhang Hua Wei (*Executive Director*)

Mr. Wang Yi (*Executive Director*)

Mr. Gong Jian Bo (*Executive Director*)

Mr. Xia Lie Bo (*Executive Director*)

Mr. Chen Xue Li (*Non-executive Director*)

Mrs. Zhou Shu Hua (*Non-executive Director*)

Mr. Lo Wai Hung (*Independent non-executive Director*)

Mr. Li Jia Miao (*Independent non-executive Director*)

Mrs. Fu Ming Zhong (*Independent non-executive Director*)

Mrs. Wang Jin Xia (*Independent non-executive Director*)